Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA Approves Daraxonrasib: First-in-Class RAS Inhibitor for Metastatic Pancreatic Cancer

27 August 2026 · By · Wire by Fusion42

Published

27 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at oncodaily.com →

◆ Verified

Fusion42 · 28 August 2026 · Fusion42 review

The FDA approved daraxonrasib, the first RAS-targeted therapy for metastatic pancreatic cancer, based on the phase 3 RASolute 302 trial showing significant overall survival benefits compared to chemotherapy.

This Wire brief sits within Fusion42's coverage of Biotech, and 34 sources have reported it between 26 Aug 2026 and 27 Aug 2026.

◆ ◆ The Wire takeaway

Daraxonrasib clearance opens a new market for pancreatic cancer therapies beyond chemotherapy. You must now target RAS mutations in your drug development to stay relevant in oncology pipelines.

◆ Coverage

34 sources · first reported 26 Aug 2026 · latest 27 Aug 2026

◆ Topics

Biotechfda-approvalpancreatic-cancerras-inhibitorclinical-trialoncology